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Superparamagnetic iron oxide nanoparticles (SPIONs) are one of the most versatile and safe nanoparticles in a wide
variety of biomedical applications. In the past decades, considerable efforts have been made to investigate the potential ad-
verse biological effects and safety issues associated with SPIONs, which is essential for the development of next-generation
SPIONs and for continued progress in translational research. In this mini review, we summarize recent developments in
toxicity studies on SPIONs, focusing on the relationship between the physicochemical properties of SPIONs and their
induced toxic biological responses for a better toxicological understanding of SPIONs.
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oxygen species
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1. Introduction
Nanotechnology is an emerging field with growing in-
terest for its numerous applications ranging from informa-
tion technologies to medicinal applications.[1] In 2008, the
International Organization for Standardization (ISO) classi-
fied nanomaterials into three main groups, i.e., nanoparticles,
nanoplates, and nanofibers.[2] A nanoparticle is defined as a
material with all three external dimensions on a nanoscale
(1 nm–100 nm). The dramatic increase in the use of nanoparti-
cles in research, industry, and medicine has raised many ques-
tions about the potential toxicity.[3]
Among the most promising nanoparticles, superparam-
agnetic iron oxide nanoparticles (SPIONs) are the only mag-
netic nanoparticles that have been approved for clinical use to
date.[4] SPIONs consist of magnetite (Fe3O4) or maghemite
(γ-Fe2O3) cores coated with biocompatible organic/inorganic
polymer. They show some unique properties such as super-
paramagnetism, high field irreversibility, high saturation field,
and extra anisotropy contributions or shifted loops after field
cooling.[5] Because of their versatile properties and biocom-
patibility, SPIONs have attracted a great deal of research in-
terest and have been broadly used in bioscience and clini-
cal research, including cell sorting;[6,7] tissue repair;[8–10] tar-
geted drug delivery;[11–14] contrast agents for magnetic reso-
nance imaging (MRI);[15,16] hyperthermia and magnetic field
assisted radionuclide therapy.[17–21]
The increasing applications of SPIONs are accompanied
with many risks and concerns on their toxicological prop-
erties and long-term influence on human health,[22–24] since
the nanoscale properties can potentially induce cytotoxic-
ity by impairing the functions of mitochondria, nucleus and
DNA.[3,25–27] In the past decades, considerable efforts have
been made to investigate the potential adverse biological ef-
fects and safety issues associated with SPIONs.[28–33] Those
nanotoxicity studies in this area lead to the required infor-
mation to make responsible regulatory decisions for future
nanomedicines. The aim of this minireview is to summarize
the current toxicity studies on SPIONs and explore the rela-
tionship between the physicochemical properties of SPIONs
and their induced toxic biological responses.
2. Mechanism of toxicity
To date, much attention has been paid to the biocom-
patibility of SPIONs in the human body. Many studies have
demonstrated that at doses of 100 µg/mL or higher, SPIONs
with varying physicochemical characteristics may cause low
toxicity or cytotoxicity (Fig. 1). As is well known, exces-
sive reactive oxygen species (ROS), including free radicals
such as the superoxide anion, hydroxyl radicals and the non-
radical hydrogen peroxide, contribute to most intracellular and
in vivo toxicities from SPIONs.[3,34,35] Because of their unique
physicochemical properties, SPIONs present a large surface
area for the generation of free radicals as a result of redox cy-
cling at the particle surface. The ROS can also be generated
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from the leaching of iron ions from the surface degradation by
enzymatic degradation. Subsequently, the ROS are transferred
to the interior of the cell where they can produce oxidative









Fig. 1. Mechanism of cytotoxicity induced by SPIONs.
Furthermore, ROS can react with macromolecules and
damage cells by peroxidizing lipids, changing proteins, dis-
rupting DNA, interfering with signaling functions, and modu-
lating gene transcription and finally causing cell death either
by apoptosis or necrosis. It was found that alterations of intra-
cellular signaling and pre-inflammatory response induced by
SPIONs are correlated with the toxicity profiles of SPIONs.
For example, cytosolic calcium is a key intracellular signal-
ing molecule that controls a variety of cellular processes,[40]
where ROS and oxidative stress resulting from SPIONs can
modulate intracellular calcium signaling to activate the tran-
scription factor NFκB and production of the pro-inflammatory
cytokine TNFα .[41,42] and control inflammation.[43]
Another mechanism by which SPIONs can induce toxi-
city is via iron overload, which has toxic implications as ex-
cessive accumulation of the SPIONs. Since SPIONs are re-
quired to be magnetically targeted to a particular tissue/organ
in biomedical application, high concentration of iron would be
localized in the targeted tissue/organ.[44] Subsequently, high
levels of free Fe ions in the exposed tissue can lead to an
imbalance in its homeostasis and can cause aberrant cellular
responses including cytotoxicity, oxidative stress, epigenetic
events, inflammatory processes, and DNA damage,[26,45–47]
which may initiate carcinogenesis or have a significant influ-
ence on future generations.[48] Furthermore, excess iron is as-
sociated with an increasing risk of cancer, particularly liver
cancer. One of the important mechanisms is that iron, not
only as a catalyst but also as a reactant, may contribute to
free radical generation, which can promote the oxidation of
proteins, peroxidation of membrane lipids, and modification
of nucleic acids.[49–52] For example, Bhasin et al.[53] reported
that spindle cell sarcoma and pleomorphic sarcoma were asso-
ciated with iron-overload following intramuscular injections
of SPIONs in rats.
3. In vitro cytotoxicity
The in vitro methods are extremely valuable for SPION
safety assessments because they can produce specific and
quantitative toxicity measurements rapidly and inexpensively
without the use of animals. Nanoparticles often affect the
metabolic activity of cells, membrane integrity of the cells,
cell apoptosis, and proliferation. Therefore, the potential in
vitro toxicity of SPIONs is initially determined as the viabil-
ity of cells, cytotoxicity, oxidative stress, inflammatory reac-
tions, and genotoxicity (Table 1).[54] Many assays have been
widely used such as the lactate dehydrogenase (LDH) assay of
cell membrane integrity, the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay for mitochondrial














Fig. 2. In vitro nanotoxicity assays for SPIONs.
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However, in vitro assays should be carried out with care
since cells in culture do not experience the phase of pathogenic
effects observed in vivo. And SPIONs can also interact with
the assay components, interfere with the readout and some-
times contribute to erroneous results. For examples, in the
classical dye-based assays such as MTT, the results would be
disturbed by SPIONs due to the absorption of dye or dye prod-
ucts and the effect of ROS induced by SPIONs on the activity
of mitochondrial enzymes. Additionally, some inherent issues
such as dose, time and interaction between cells and matrix
should be considered as well while analyzing the results, since
they can also contribute to invalid data. Furthermore, because
of the great difference between two-dimensional (2D) cells
and three-dimensional (3D) tissues, one should be careful to
apply the cell culture results to 3D tissues. The 2D cell cul-
ture may not accurately reflect the actual toxicity of SPIONs
in vivo as it could not adequately represent the functions of 3D
tissues, which have extensive cell-to-cell and cell-to-matrix in-
teractions and different transport conditions.
The cytotoxicity of SPIONs was found to be highly de-
pendent on a range of factors related to their physical proper-
ties, such as size, shape and surface coating. With the increase
of particles’ size, the area of surface increases, which becomes
more reactive toward surrounding biological components and
affects the biocompatibility of nanoparticles. A shape depen-
dent nanotoxicity has been observed in a series of studies on
different nanoparticles. The observed particle shapes include
spherical shape, nanoworms, rod-shape, or magnetic beads,
each of which has its own contact area with the cells and thus
causes the difference in biocompatibility from others. For ex-
ample, rod-shape SPIONs have been found to be endocytosed
more slowly than spherical SPIONs.[55]










Dextran 15 0.05 mg/mL fibroblasts (human) 1 d–3 d BrdU result in cell death and re-
duced proliferation[59]
100–150 0.1 mg/mL macrophages (human) 7 d MTS
assay






3 d neutral red
assay
1 mg/mL no toxic
10 mg/mL mildly toxic[96]
20, 60 0.2–20 µM primary peritoneal macrophages
(rats and mice)
15 min–2 d cytokine
determi-
nation
result in an increased se-
cretion of anti-inflammatory
cytokines, and reduced pro-
duction of pro-inflammatory
cytokines[97]
0, 1, 10, 100 µg Fe/mL raw 264.7 (murine macrophage) 24-h MTT, try-
pan blue
no significant difference be-
tween cells exposed to 0,




12.5 800 mM L929 (mouse) 3 d Crystal vi-
olet
confirmed the existence of




0.2, 1, 5, and 20 mM L929 (mouse) 3 h, 1 and 2 d MTT Toxicity was dependent on
nanoparticle morphology
and size[99]
82 0.4, 0.8, and 1.6 mM L929 (mouse) 1, 2 and 3 d MTT Toxicity was dependent on
nanoparticle morphology
and size[100]
Silica 50 4 mg/mL A549 (human) MTT IC50 = 4 mg/mL[101]
30–120 10 µg/mL macrophages and dendritic cells
(human)








80–150 50 µg/mL–250 µg/mL MSC (human) 1 d–3 d Comet no mediated apoptosis in la-
beled MSCs.[104]
Uncoated 20–30 up to 80 µg/mL A549 (human) 18 h TB and
ROS
no or low toxicity[105]
Uncoated 30, 47 up to 250 µg/mL BRL 3A (rat) 1 d LDH no toxicity up to 100 µg/mL
and significant toxic effects
at 250 µg/mL[106]
The type of surface-coating materials of SPIONs and
their breakdown products are important to determine their
toxicity.[56] Uncoated SPIONs have very low dispersibility
that can lead to precipitation and a high rate of agglomera-
tion under physiological conditions. Proper coating can not
only stabilize SPIONs, but also prevent the dissolution and
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release of toxic ions. SPIONs are usually designed to be
coated with an amphiphilic layer or bound to complex bio-
logical molecules such as antibodies, peptides, hormones or
drugs.[57] The most common coatings are derivatives of dex-
tran, polyethylene glycol (PEG), polyethylene oxide (PEO),
poloxamers, and polyoxamines.[58] The cytotoxic potential of
SPIONs with a range of surface coatings has been extensively
investigated. For example, it was demonstrated that PEG-
coated SPIONs produced negligible aggregation in cell cul-
ture media and reduced nonspecific uptake by macrophage
cells.[21] However, Berry et al.[59] found that dextran-coated
SPIONs could cause cell death and reduce proliferation similar
to that caused by uncoated SPIONs. In the further study, sig-
nificant membrane disruptions were observed in cells treated
with dextran-coated SPIONs,[60] which may be attributed to
the interactions among albumin, membrane fatty acids and
phospholipids.
Cell culture medium is an important factor to influence
the toxicity of SPIONs. Negatively charged uncoated SPI-
ONs could bind to the serum proteins of cell culture medium
and induce denaturation of proteins, which in turn can cause
cytotoxicity.[61] Cell culture medium can also influence col-
loidal stability and cell interaction of SPIONs. Serum in the
culture medium could induce agglomeration of the vinyl al-
cohol/vinyl amine copolymer-coated SPIONs and strongly in-
hibit cellular uptake of SPIONs.[62] Furthermore, proteins and
other nutrients in cell culture medium may be adsorbed onto
SPIONs and become unavailable for cellular activities, leading
to the changes of cell growth and viability. Therefore, differ-
ent medium recipes could influence the outcome of SPION cy-
totoxicity and optimal culture medium should be determined
individually according to the type of SPIONs.[63,64]
The oxidation state of iron (Fe2+ or Fe3+) in SPIONs
is an additional key factor that determines the cytotoxicity of
SPIONs.[48] Fe3+ ions are much more potent in inducing DNA
damage than Fe2+. It has been demonstrated that maghemite
(Fe2O3) with an Fe2+/Fe3+ ratio of 0.118 has a more signifi-
cant genotoxicity than magnetite (Fe3O4) with an Fe2+/Fe3+
ratio of 0.435. Much more effort is required to design and
prepare SPIONs with good chemical stability.
4. In vivo toxicity of SPIONs
In vitro assays to investigate the toxicity of SPIONs are
simpler, faster, and more cost-effective without ethical prob-
lems. However, little correlation between in vivo and in vitro
toxicity of SPIONs has been demonstrated.[65] Researchers
have found that some toxic responses of cells observed for
SPIONs in vitro[66] were not exactly reproduced in vivo.[67]
This may be attributed to the homeostasis maintained by the
liver and kidneys, which could efficiently regulate any changes
in pH, ionic strength and chemical composition of the blood
plasma in the body.
Despite cost, time, and ethical considerations, in vivo
tests in animal models are crucial for the study of SPION bi-
ological effect. In vivo assays have several priorities when
studying the toxicity of SPIONs, such as determining the
toxico-kinetics in the body (i.e., absorption, distribution,
metabolism, and elimination) and evaluating the immunolog-
ical, neurological, reproductive, cardiovascular and develop-
mental toxicities to determine the chronic systemic toxicity of
SPIONs.[23] Therefore, in order to understand their activity
and potential toxicity it is necessary to conduct a systematic
analysis of the pharmacokinetics of SPIONs, which can lead
to improvements in the design of biocompatible SPIONs, a
better understanding of SPION non-specificity toward tissues
and cell types, and assessments of their basic distribution and
clearance in the body.[68,69]
Generally, SPIONs are classified as biocompatible
ones without severe toxic effects in vivo (Table 2).[70,71]
However, the toxicity of SPIONs can be considered to
be dose-dependent.[72] For example, intravenously injected
Ferumoxtran-10 (dextran-coated SPIONs) at a dose of 2.6 mg
Fe/kg in rats produced no changes in hemodynamic parame-
ters whereas 13 mg Fe/kg dose caused a noticeable increase
in aortic blood flow, but without any treatment-related cardio-
vascular or respiratory toxicity. The treatment-related clini-
cal signs were observed only at a very high single dose (e.g.,
126 mg Fe/kg, a dose 45 times higher than that used in human
as MRI contrast agents). Additionally, repeated intravenous
injection (3 ∼ 5 times) at a dose of 17.9 mg Fe/kg in rats could
lead to moderate changes in hematological parameters. Neu-
rotoxicity study of ferumoxtran-10 showed some minor side
effects on the central nervous system, including a lowered or
increased spontaneous locomotor activity, rearing, exophthal-
mos, or mydriasis.[73] After injection of SPIONs, the serum
iron level was noticeably increased. The chronic iron toxic-
ity in humans may occur after administration of high doses of
iron.
It is noteworthy to mention that the biological fate of SPI-
ONs is strongly dependent on the composition and quantity
of associated proteins at the surface of SPIONs,[74] which are
determined by the physicochemical properties of SPIONs in-
cluding surface morphology, surface charge density, coating
material, nanoparticle size, and size distribution. Addition-
ally, tissue/cell type is another crucial factor to influence the
toxic response of SPIONs. For example, Hanini et al.[70] re-
ported that SPIONs in vivo could induce toxicity in the liver,
kidneys, and lungs while the brain and heart organs remained
unaffected.
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Table 2. In vivo toxicity results of SPIONs.
Toxicity study Nanoparticle
used





552 mg/mL wistar rats subcutaneous implant relatively inert with slow, progres-
sive local degradation over the
six-month period and no distict




γ−Fe2O3 0.8 mg/kg wistar rats intravenous injection;
tail vein injection for
clearance study
rapidly cleared through the urine;
lead to toxicity in the liver, kidneys
and lungs, the brain and heart re-
main unaffected[70]
Pulmonary toxicity and
kinetic profile of TCL-
SPIONs
TCL-SPIONs 0.6, 1.8, and 5.4 mg/kg
for acute toxicity study,
1.8 mg/kg for kinetic study
BALB/c mice intratracheally instil-
lation
slightly induced pulmonary in-
flammation, distributed mainly in








10 mg Fe/kg. sprague-
Dawley rats
tail vein injection did not cause long-term changes in




in two animal models




tail vein injection no toxicity[109]
The selectivity of SPI-




12 mg Fe/kg male Fisher
344
rats
intravenous injection accumulation of SPIONs in
gliosarcomas is enhanced by mag-
netic targeting; quantified by MRI





12.5 mg Fe/kg, 0.64 mg
Dox/kg
mice intravenous injection no toxicity in the major organs[111]
Safety evaluation of an
undiluted direct injection
of ferumoxides
ferumoxides 0.56 mg Fe/kg patients with
focal liver le-
sions
direct injection direct injection of ferumoxides has
safety and effectiveness profiles
similar to those of slow infusion of
the agent[112]
5. Blood compatibility
In terms of in vivo application of SPIONs, blood com-
patibility is an essential property. Should SPIONs be incom-
patible with bio-fluids such as blood, this could trigger co-
agulation and clot formation through adsorption of plasma
proteins, platelet adhesion and activation of complement cas-
cades. One of the primary screening tests on SPIONs tox-
icity is the haemolysis assay by using mammalian erythro-
cytes. The coagulation tendencies can be evaluated using
widely available clinical assays including prothrombin time,
activated clotting time, activated partial thromboplastin time
and thrombin time,[23] which are useful in evaluating the in-
trinsic and extrinsic effects of SPIONs on the blood coagu-
lation cascades. Intravenous injection (5 µM Fe/kg–40 µM
Fe/kg) of Ferucarbotran, a clinically approved SPIONs coat-
ing with carboxydextran, was demonstrated to be safe except
for a transient decrease in the specific clotting activity of blood
coagulation Factor XI, which did not cause any clinically rel-
evant adverse effects.
6. Biodistribution and elimination
The biodistribution of SPIONs used as an intravenous
contrast agent for MRI is most widely studied.[58,75] After in-
travenous administration, SPIONs are distributed to various
organs and tissues such as colon, lungs, bone marrow, liver,
spleen, and the lymphatics.[76–78] The typical final biodistri-
bution of SPIONs is 80%–90% in liver, 5%–8% in spleen
and 1%–2% in bone marrow.[79,80] The physicochemical char-
acteristics of nanoparticles such as size, surface morphol-
ogy and surface charge, could influence their tissue distri-
butions. After cellular uptake, SPIONs commonly reside in
endosomes/lysosomes where they decompose into free iron,
which is slowly released to the cytoplasm and eventually con-
tributes to the total cellular iron pool.
The distribution of SPIONs is followed by rapid clear-
ance from the systemic circulation, predominantly by action
of the liver and spleen macrophages.[81] Generally, clearance
and opsonization of SPIONs depend on their sizes and sur-
face characteristics.[82,83] Differential opsonization accounts
for variations in clearance rates and macrophage sequestra-
tion of SPIONs.[83] For example, 55% oleic acid/pluronic-
coated SPIONs of injected dosage were accumulated in the
liver of a rat. However, in the same animal model, 25% of in-
jected dextran-coated SPIONs were eliminated via urine and
feces.[84] Similarly, the distribution and elimination results ob-
tained with ferumoxtran-10, a specific type of ultrasmall SPI-
ONs coated with low molecular weight dextran, showed only
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∼ 20% of the iron ions injected were eliminated after 2 months
through urine and feces in different animal models.[85] More
attention should be paid to the mapping of the fate, kinetics,
clearance and metabolism of SPIONs with different surface
coatings, which would allow the development of predictive
models of nanotoxicity (Fig. 3).[86]
SPIONs have many potential diverse applications and
therefore there are a number of expected administration routes
associated with the utilization of SPIONs. The distribution
of SPIONs can be influenced by administration route. When
being injected locally at the diseased site (e.g., tumor), SPI-
ONs can undergo passive movement into the interstitial spaces
around the administration site and gradually flow into lym-
phatic system. It was found that the inhaled SPIONs could
cross the tight junctions/barriers such as the pulmonary epithe-
lium, the blood-brain and blood-testis endothelium. Kwon et
al.[87] reported that SPIONs administered by inhalation route
to mice through the nose for 1 month, accumulated into the
liver followed by testis, spleen, and brain. Intraperitoneally
injected SPIONs were also distributed at high concentrations
into the spleen and liver. Interestingly, SPIONs could cross
the intact blood-brain barrier and were taken up by the neu-
ronal cells.[28]
Fig. 3. Schematic overview of biodistribution, degradation, and clearance of PEGylated SPIONs in the liver. The SPIONs suitable for
clinical translation require the optimization of pharmacokinetic/pharmacodynamic (PK/PD) to match residence time with the imaging
needs. Reproduced with permission.[86] Copyright 2012, American Chemical Society.
7. In silico assays for nanotoxicity
An in silico method is a kind of fast and cost efficient
approach to predict the nanotoxicity through integrated com-
putational systems accounting for multiple variables associ-
ated with the biological interactions, which can supplement
or replace some expensive and time-consuming assays, espe-
cially in the early design process of new types of SPIONs. By
using computer-aided simulation, Dames et al.[88] observed
that targeted aerosol delivery to the lung can be achieved with
aerosol droplets comprising SPIONs in combination with a
target-directed magnetic gradient field, which has been ex-
perienced in mice for the first time. Mathematical models
were also developed by Sayes and Ivanov[89] to predict cellu-
lar membrane damage resulting from nanoparticles. Recently,
Puzyn et al.[90] predicted the toxicity of 17 different metal ox-
ide nanoparticles by using in silico assays. Such a method
shows great potential for the future design of safe SPIONs.
However, in silico assay requires well-defined biological,
toxicological, or pharmacological endpoints observed with
similar nanoparticles, while for newly engineered nanoparti-
cles, few toxicological or pharmacological data are available.
Furthermore, as far as the accuracy is concerned, the results
from in silico methods cannot be expected to exceed the data
used to construct the model. Therefore, it is essential to val-
idate the results of the mathematical model by using in vivo
evaluation.
8. Surface engineering for SPIONs-based nano-
medicine
Appropriate chemical design of both the core and the
shell of SPION is extremely important for medical applica-
tions since naked SPIONs are quite unstable and even form
bulk aggregates in biological fluids (i.e., blood). Gener-
ally, “green chemistry” avoiding the use of toxic chemicals
is strongly recommended to prepare SPIONs suitable for pre-
clinical and clinical applications and has attracted many efforts
toward this goal. Owing to the progress in synthesis and sur-
face modification, many new or improved methods have been
developed to load a wide range of functionalities onto SPION
surfaces, which can enhance its biological compatibility for
SPION-based nanomedicine.[21]
Until now, a wide range of monomers, polymers, and
inorganic biomaterials have been used for coating SPIONs,
which provides a protective shell to stabilize SPION, avoid
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agglomeration and prevent the dissolution and release of toxic
ions. The coating materials on SPIONs are required to be
biocompatible and biodegradable to avoid immune response
and nonspecific adsorption of serum proteins after the in-
travenous administration. Biodegradable polymers such as
dextran and carbohydrate derivatives are traditionally used as
coating biomaterials of SPIONs to accomplish multiple pur-
poses including enhancing the colloidal stability, increasing
the blood circulation time and improving the biocompatibil-
ity of nanoparticles. Taking Feridex (FDA approved SPIONs)
as an example, the surface coating of dextran can angle with
the growing SPIO nanocrystals, protecting them from over-
growing and aggregating. Although the marketed or clinical-
trial SPIONs (i.e., Combidex, Feridex and Resovist) are all
coated with dextran or its derivatives, other hydrophilic poly-
mers such as polyaspartic acid were demonstrated to be able
to substitute dextran for SPION surface engineering. Addi-
tionally, polyethylene glycol (PEG), one of the most impor-
tant hydrophilic polymers approved by FDA, is hemocompat-
ible, non-antigenic and non-immunogenic with less side ef-
fects, which allows its extensive application for coating SPI-
ONs.
Recently, high quality SPIO nanocrystals were synthe-
sized in organic phase at higher temperatures for the bet-
ter controlling of particle size and morphology.[91] However,
these SPIO nanocrystals can be dispersed very well only in
some organic solvents (i.e., chloroform, hexane, and tetrahy-
drofuran) with the coating of hydrophobic materials (i.e., oleic
acid and oleylamine). Hence, it is quite necessary to transfer
hydrophobic SPIO nanocrystals into a water phase with the
help of amphiphilic biomaterials for certain biological applica-
tion. To address such an issue, many surface engineering tech-
niques have been developed, such as exchanging ligand and
physical encapsulation, to increase the stability and biocom-
patibility of SPIONs. For example, we have tried to use lig-
ands such as dopamine which has high affinity toward SPION
surfaces. When being mixed, dopamine can cover the original
coating oleic acid/oleylamine and lead to hydrophilicity.[21]
Polymeric micelles have emerged as good carriers for
hydrophobic SPIO nanocrystals. They can solubilize SPIO
nanocrystals in their inner cores and offer attractive character-
istics such as a generally nanoscale size (10 nm–100 nm) and
a propensity to evade scavenging by the mononuclear phago-
cyte system. Recently, Alkylated polyethylenimine (PEI), a
typical amphiphilic block copolymer, was demonstrated to be
used to form multiple SPIO nanocrystals containing micelles
in aqua phase for cell labeling and MRI.[14,91] The polymer-
encapsulated method is very flexible since it allows fir the
preparation of SPIONs carrying a wide variety of stabilizers.
With the progress of surface engineering, there is a grow-
ing interest in developing SPIONs harboring various func-
tions including cancer targeting, imaging, therapy, etc. Var-
ious kinds of antibodies, peptides and aptamers have been at-
tached to SPIONs as targeting probes for specific biomark-
ers on target cells, providing a powerful route to the forming
of multifunctional SPIONs for nanomedicine (Fig. 4).[21,92] In
general, SPION surface engineered with targeting ligands has
a large attractive force to bind the specific cells for targeted
imaging/therapy. A typical experiment to test the SPIONs for
their targeting effectiveness uses in vitro cultured cells that ex-
press unique biomarkers. Additionally, xenograft animal mod-
els are also widely used to evaluate SPIONs and explore basic
pathophysiological mechanisms. However, it is noticeable that
human tumors are often much more complex than the tumor
xenografts in animal models, which could hinder the develop-
ment of targeting SPIONs.
Fig. 4. Schematic diagram of the proposed protection mechanism of
SPIONs coated with platelet endothelial cellular adhesion molecule-
1antibodies (antiPECAM-1) and a targeted polymeric antioxidant
(PTx). The antiPECAM-1/PTx SPIONs can bind to and internalize in
endothelial cells and provide localized protection against the potential
toxicity caused by SPIONs. Reproduced with permission.[92] Copyright
2013, Elsevier.
Surface charge plays a significant role in colloidal sta-
bility due to the behavior of the surface group in solution
at a certain pH. Furthermore, the surface charge is one of
the most important issues that affect the cell-nanoparticle
interactions.[93] It can influence the cellular uptake efficiency
of SPIONs, change organism/cellular responses to SPIONs
and affect plasma protein binding hence the organ distribu-
tion and clearance of SPIONs (Fig. 5).[33,94] In general, sur-
face functionalization with a positively charged group could
enhance the uptake of SPIONs into cells. However, cationic
surfaces with excess iron cations may induce hemolysis and
platelet aggregation, which may be due to the affinity of
cationic SPIONs to the negative phospholipid head groups or
protein domains on cellular membranes.
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Fig. 5. Schematic overview of biocompatibility in vitro, and long-term biodistribution/clearance in vivo of SPIONs surface engineered
with dimercaptosuccinic acid (DMSA). Negatively charged DMSA-SPIOs accumulating in liver tissues for extended periods of time
could undergo a process of conversion from SPIOs to other non-SPIOs forms. The in vivo biotransformation confirms the promise of
DMSA-coated SPIOs for clinical use. Reproduced with permission[94] Copyright 2013, Elsevier.
9. Conclusions and perspectives
Considering the wide preclinical and clinical applications
of engineered SPIONs in the context of nanomedicine, it is
crucial to understand the potential risks associated with expo-
sure to SPIONs and the physiological effects produced by the
surface coatings utilized for functionality. In this mini review,
we first review the known mechanisms by which SPIONs can
damage cells, including oxidative stress elicited by ROS. We
provide a general discussion on the in vitro and in vivo toxi-
cities of SPIONs while there are still a number of issues that
need be clearly addressed prior to approving their clinical use.
This field of nanotoxicity is important for the advancement of
SPIONs in a wide range of applications. Studies in this field
could lead to the required information to make responsible reg-
ulatory decisions for the development of next-generation SPI-
ONs and for continued progress in translational research.
Some challenges need to be addressed including appro-
priate methods to assess the toxicity of novel SPIONs, such
as generating gold standard and reference biomaterials for
nanosafety testing, establishing ex vivo models for the specific
routes of administration of nanomedicines, and developing in
silico model approaches to predict the toxicological responses
of SPIONs. As epigenetic changes may cause the reprogram-
ming of gene expression long after the initial insult has been
removed, epigenetic assessments should be tested early in the
development of new SPIONs.
More work should be done on the design of function-
alized SPIONs, which can not only be effectively and suf-
ficiently internalized and are appropriately magnetisable, but
also meet the demands of a particular application at the ex-
pense of no cellular toxicity. As for the in vivo pharma-
cokinetic studies on SPIONs, detection strategies must be
capable of quantifying all of the major parts of SPIONs in
tissues/organs since many multifunctional SPIONs are engi-
neered with multiple components. Traditional radiolabeling
of surface molecules coating on the SPIONs core is easily
achieved, but the pharmacokinetic results might be mislead-
ing. In order to qualify the observed in vivo results, it is very
important to understand how proteins interact with SPION sur-
faces, since this can potentially control the behavior of SPI-
ONs in vivo. However, the studying of the toxicity aspects
of SPIONs is lagged far behind their rapid development, and
understanding the dynamic and complex interactions between
SPIONs and biological systems is far from being complete.
All of these factors give rise to conflicting results and slow
down the development of this field.
In summary, the comprehensive characterization of SPI-
ONs is often neglected prior to using them. It is crucial to en-
courage interdisciplinary research in the nanomedicine from
the clinical, biological, engineering and toxicological point of
view. Through the persistent efforts by multidisciplinary ap-
proaches, there is a great potential for further breakthrough de-
velopments in SPION designs for nanomedicine, which could
solve the problem of “nanotoxicity” in the near future.
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